Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q2 2025 · 10-Q
Revenue$518.00K$518.00K+398.1% vs Q2 2024 Net Income-$9.74M-$9.74MN/M vs Q2 2024 EPS Diluted-$0.30-$0.30N/M vs Q2 2024 Gross Profit$338,000+576.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flowderived-$6,174,000N/M Free Cash Flowderived-$6,523,000N/M Margins · derivedGross margin65.3%+17.2 pt vs Q2 2024
Operating margin-1900.0%+2553.8 pt vs Q2 2024
Net margin-1880.7%+2475.1 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end